Apple Tree Partners is a New York-based venture capital firm founded in 1999 that focuses on investments in biotechnology and life sciences. The firm collaborates with scientists and executives in the biopharmaceutical and medical device sectors to create innovative, market-driven companies. Apple Tree Partners primarily invests in proprietary products and technologies that address unmet market needs. While the firm prefers to initiate new companies, it also engages with assets at various stages of development. To enhance its investment capacity, Apple Tree Partners often seeks collaboration through syndication with larger venture firms, corporate partnerships, and creative financing solutions.
Adendra is an emerging biotechnology company building on new insights into dendritic cell biology to discover and develop new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases.
Developer of immune activation therapeutics intended to treat cancer. The company's antibodies induce targeted and durable anti-tumor activities in malignant solid tumor models and promote protective tumor immunity while triggering cytokine release for the expansion of an antigen-specific memory T cell repertoire, enabling patients to face challenging and life-threatening diseases for better treatment.
Developer of a focal non-viral gene therapy designed to overcome the limitations of viral-based gene therapy. The company's therapy uses synthetic biology and engineered gene circuits to make covalently closed and circular deoxyribonucleic acid molecules, providing healthcare professionals with access to new gene therapies which safety issues, and technical obstacles have beset.
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.
Developer of medical technologies designed to treat patients suffering from cardiac arrhythmia. The company's device uses pulsed electric field technology which utilizes high voltage, high-frequency bursts of electro-surgical energy to ablate tissue, enabling electrophysiologists to deliver safe and effective patient-centered ablation procedures, resulting in better medical outcomes.
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.
Developer of immune activation therapeutics intended to treat cancer. The company's antibodies induce targeted and durable anti-tumor activities in malignant solid tumor models and promote protective tumor immunity while triggering cytokine release for the expansion of an antigen-specific memory T cell repertoire, enabling patients to face challenging and life-threatening diseases for better treatment.
Operator of a biotechnology company intended to design exon-editing RNA therapeutics to target the underlying causes of disease. The company excises disease-causing genes and replaces them with wild-type to restore normal protein production in a single reaction with a single construct, helping medical professionals redefine the treatment of disease by rewriting the genetic code.
Developer of a focal non-viral gene therapy designed to overcome the limitations of viral-based gene therapy. The company's therapy uses synthetic biology and engineered gene circuits to make covalently closed and circular deoxyribonucleic acid molecules, providing healthcare professionals with access to new gene therapies which safety issues, and technical obstacles have beset.
Nereid Therapeutics is a Cambridge, Massachusetts-based company dedicated to discovering small molecule treatments for diseases by targeting protein interactions through the process of liquid-liquid phase separation. Utilizing proprietary technologies, Nereid focuses on generating, visualizing, and measuring the resulting biomolecular condensates to develop innovative therapeutic solutions.
Developer of medical technologies designed to treat patients suffering from cardiac arrhythmia. The company's device uses pulsed electric field technology which utilizes high voltage, high-frequency bursts of electro-surgical energy to ablate tissue, enabling electrophysiologists to deliver safe and effective patient-centered ablation procedures, resulting in better medical outcomes.
Nine Square Therapeutics
Series A in 2020
Nine Square Therapeutics is discovering new small-molecule therapeutics for degenerative movement disorders including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), as well as non-degenerative disorders such as essential tremor and dyskinesias, by integrating computational chemistry, biophysics, and computational biology into machine-learning-enabled cell profiling platforms for target identification, chemical optimization, and patient stratification. It was founded in 2020 and headquartered in New York, United States.
Limelight Bio is a multi-platform, multi-disease focused biopharmaceutical company expanding the limits of gene therapy. The company is developing novel gene therapies that greatly expand the utility of clinically-validated AAV vectors to enable the treatment of debilitating inherited diseases that cannot be addressed by current technologies; such as those caused by mutations in large genes and autosomal dominant inheritance patterns.
Limelight Bio's proprietary technologies are designed to overcome limitations of currently available viral-based treatments to address a wider range of diseases. It was founded in 2016 and is headquartered in Philadelphia, Pennsylvania, United States.
Gala Therapeutics is a privately-held medical device company based in Menlo Park, California, focused on developing disease-modifying therapies for patients with lung cancer, chronic obstructive pulmonary disease (COPD), asthma, and other pulmonary diseases. Founded in 2015, the company aims to enhance survival rates and improve the quality of life for patients. Its innovative therapies cater to the needs of interventional pulmonologists, thoracic surgeons, and other healthcare professionals, enabling them to deliver more effective treatments and achieve better medical outcomes for those suffering from pulmonary conditions.
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
The company was founded in 2019 and headquartered in Alberta, Canada.
Bellus Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, focused on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. Additionally, the company is advancing KIACTA™, a novel treatment for AA amyloidosis and sarcoidosis, both rare diseases affecting renal and pulmonary functions, respectively. KIACTA™ is in the data review stage following a Phase 3 study. Bellus Health is also developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies in progress. Furthermore, the company has a research-stage project aimed at treating AL amyloidosis, a condition characterized by the accumulation of amyloid proteins in various organs. Bellus Health is dedicated to addressing unmet medical needs through its innovative drug development pipeline.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.
Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, particularly opioid addiction. Founded in 2012 and based in Plymouth Meeting, Pennsylvania, Braeburn aims to address the significant challenges posed by opioid use disorder, a chronic condition that leads to structural and functional changes in the brain. The company's lead product is BRIXADI, an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe opioid use disorder. Braeburn is dedicated to advancing next-generation therapies that offer individualized dosing regimens and various delivery options, thereby providing effective solutions for patients, healthcare providers, and society at large.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Elstar Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2015. The company focuses on developing innovative immunotherapies aimed at treating a range of diseases, particularly in the fields of oncology and autoimmunity. Elstar Therapeutics is dedicated to advancing precision cancer immunotherapy by creating antibody-based, multi-functional therapeutics that enhance treatment efficacy.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.
QualDerm Partners specializes in providing strategic leadership and management services to dermatologists and skin care professionals in the southeastern United States. By offering operational support and administrative resources, the company enables healthcare providers to concentrate more on patient care rather than on administrative tasks. QualDerm Partners promotes a practice-centric philosophy, fostering a culture that prioritizes effective management and sustainable growth for dermatology practices. Their services include management support, capital, and guidance, empowering physicians to efficiently oversee all aspects of patient care while enhancing the overall profitability of their practices.
Cure Forward is a healthcare company based in Boston, Massachusetts, that focuses on genomic medicine and oncology. Founded in 2014, it operates an online portal designed to provide patients and physicians with access to genomic testing data. This platform enables users to explore and identify advanced treatment options, particularly for cancer patients. By facilitating communication and information sharing between patients and healthcare providers, Cure Forward aims to enhance the decision-making process in clinical trials and treatment selection.
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities.
It was founded in 2010 and headquartered in Menlo Park, California.
Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases, with a particular focus on inherited metabolic disorders. The company's pipeline includes therapies such as CERC-801, CERC-802, and CERC-803, which have completed phase I clinical trials. Additionally, Cerecor is developing CERC-007, an anti-IL-18 monoclonal antibody for autoimmune inflammatory diseases, and CERC-006, a dual mTOR inhibitor for complex lymphatic malformations. Other notable developments include CERC-002 for pediatric-onset Crohn's disease, CERC-913 for mitochondrial disorders, and CERC-005 for rare auto-inflammatory diseases. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions. Founded in 2011 and headquartered in Rockville, Maryland, the company was previously known as Ceregen Corporation before rebranding in March 2011.
Tendyne Holdings Inc. develops medical device for transcatheter mitral valve replacement, repair, and targeting mitral regurgitation. The company was incorporated in 2010 and is based in Roseville, Minnesota. As of August 2015, Tendyne Holdings Inc. operates as a subsidiary of Abbott Laboratories.
Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.
Cyrano Sciences, is focused on providing chemical and biological sensors and software solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.